Stockscreener 앱 받기
9.4551
3.27%
-0.3199
시간 외 거래:
9.50
0.0449
+0.47%
전일 마감가:
$9.775
열려 있는:
$10.35
하루 거래량:
60,968
Relative Volume:
1.05
시가총액:
$258.97M
수익:
-
순이익/손실:
$-102.09M
주가수익비율:
-9.0049
EPS:
-1.05
순현금흐름:
$-108.72M
1주 성능:
-5.45%
1개월 성능:
+9.43%
6개월 성능:
+117.86%
1년 성능:
+83.59%
1일 변동 폭
$9.405
$10.41
1주일 범위
$9.1312
$10.41
52주 변동 폭
$2.2045
$12.78
Dbv Technologies Adr Stock (DBVT) Company Profile
명칭
Dbv Technologies Adr
전화
33(0)155427878
주소
107 AVENUE DE LA REPUBLIQUE, CHATILLON
DBVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
9.4551 | 267.32M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-29 | 재개 | Goldman | Sell |
| 2023-01-04 | 업그레이드 | Societe Generale | Hold → Buy |
| 2022-12-16 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-05-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-09-14 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-01-22 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2020-11-02 | 업그레이드 | Societe Generale | Sell → Hold |
| 2020-08-06 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2020-08-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-17 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-01-09 | 업그레이드 | Stifel | Hold → Buy |
| 2019-12-16 | 개시 | Citigroup | Buy |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-06-17 | 개시 | Goldman | Buy |
| 2018-12-20 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-12-20 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-12-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-10-31 | 업그레이드 | Societe Generale | Sell → Hold |
| 2017-10-24 | 다운그레이드 | Societe Generale | Buy → Sell |
| 2017-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | 개시 | Deutsche Bank | Buy |
| 2017-03-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2016-09-26 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-03 | 개시 | Barclays | Overweight |
| 2015-10-23 | 개시 | BofA/Merrill | Buy |
모두보기
Dbv Technologies Adr 주식(DBVT)의 최신 뉴스
DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Average PT from Analysts - Defense World
European ADRs Inch Higher As Drugmakers Shine - Finimize
DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer - GlobeNewswire
DBV Technologies Taps Healthcare Veteran as CHRO to Drive Commercial Evolution - Stock Titan
What analysts say about DBV Technologies S.A. Depositary Receipt stockHigh-impact stock picks - Autocar Professional
European Stocks In The US Finish With A Modest Rebound - Finimize
European ADRs Climb As Verona Pharma Leads Gains - Finimize
European ADRs Climb As Sequans Leads The Charge - Finimize
DBV Technologies’ SWOT analysis: peanut allergy patch stock poised for growth - Investing.com India
DBV Technologies (NASDAQ:DBVT) Upgraded to Hold at Wall Street Zen - Defense World
European Stocks Climb As ADRs Post Gains - Finimize
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Research Analysts Set Expectations for DBVT Q2 Earnings - Defense World
Lifesci Capital Upgrades DBV Technologies (NASDAQ:DBVT) to Strong-Buy - Defense World
European Biopharma Leads Gains In ADR Market Surge - Finimize
European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest
European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize
DBV Technologies stock holds steady as JMP reiterates $21 price target - Investing.com
Breakthrough Peanut Allergy Treatment Enters Critical Phase 3 Trial for Toddlers as Young as 12 Months - Stock Titan
European ADRs Dip As Evaxion And Grifols Climb - Finimize
European ADRs Dip While Biotech And Energy See Gains - Finimize
European Stocks Shine As ADRs Climb Higher - Finimize
DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Above 50 Day Moving Average – Here’s Why - Defense World
DBV Technologies to Participate in Upcoming EAACI Congress 2025 - The Manila Times
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting - GlobeNewswire
DBV Technologies Secures Full Shareholder Support at Annual Meeting: Key Governance Updates - Stock Titan
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document - GlobeNewswire
DBV Technologies Reveals Special CEO Pay Package Ahead of Critical Shareholder Vote - Stock Titan
European ADRs Climb With Biotech Stocks Leading The Charge - Finimize
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
DBV Technologies (NASDAQ:DBVT) Raised to Sell at The Goldman Sachs Group - Defense World
Goldman Sachs cuts DBV Technologies stock to Sell, target EUR1.30 By Investing.com - Investing.com South Africa
Goldman Sachs cuts DBV Technologies stock to Sell, target EUR1.30 - Investing.com India
Goldman Sachs reinstates DBV Technologies with sell rating, $7.25 target By Investing.com - Investing.com India
Goldman Sachs reinstates DBV Technologies with sell rating, $7.25 target - Investing.com
DBV Technologies (NASDAQ:DBVT) Price Target Raised to $21.00 at JMP Securities - Defense World
European ADRs Rise On S&P Europe Select Index - Finimize
DBV Technologies’ SWOT analysis: peanut allergy treatment stock faces pivotal trial - Investing.com
European ADRs Show Optimism As Genfit Leads Gains - Finimize
European ADRs Slip As US Index Notes Mixed Gains And Losses - Finimize
Comparing DBV Technologies (NASDAQ:DBVT) and Maze Therapeutics (NASDAQ:MAZE) - Defense World
Are You Looking for a Top Momentum Pick? Why DBV Technologies S.A. (DBVT) is a Great Choice - Nasdaq
Dbv Technologies Adr (DBVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):